Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2015 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Accumulated Expenses came in at $2.7 billion in Q2 2026, down 11.53% YoY from $3.1 billion in Q2 2025, and up 4.66% on a QoQ basis from $2.6 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2015 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 12 years of Accumulated Expenses data on file, last reported at $2.7 billion in Q2 2026.
- Quarterly Accumulated Expenses fell 11.53% year-over-year to $2.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.7 billion (down 11.53% YoY) and the FY2025 annual result came in at $2.7 billion, down 3.76% from the prior year.
- Accumulated Expenses rose to $2.7 billion in Q2 2026, from $2.6 billion in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.1 billion in Q2 2025 to a low of $2.0 billion in Q3 2022.
- A 5-year average of $2.6 billion and a median of $2.7 billion in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 40.3% — and 2023, when it decreased 12.71%.
- Tracing TEVA's Accumulated Expenses over 5 years: stood at $2.2 billion in 2022, then gained by 28.82% to $2.8 billion in 2023, then gained by 0.76% to $2.8 billion in 2024, then slipped by 3.76% to $2.7 billion in 2025, then increased by 1.9% to $2.7 billion in 2026.
- The last three Accumulated Expenses figures came in at $2.7 billion (Q2 2026), $2.6 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.74 Bn |
| Mar 31, 2026 | 2.62 Bn |
| Dec 31, 2025 | 2.69 Bn |
| Sep 30, 2025 | 2.99 Bn |
| Jun 30, 2025 | 3.10 Bn |
| Mar 31, 2025 | 2.95 Bn |
| Dec 31, 2024 | 2.79 Bn |
| Sep 30, 2024 | 2.98 Bn |
| Jun 30, 2024 | 2.84 Bn |
| Mar 31, 2024 | 2.78 Bn |
| Dec 31, 2023 | 2.77 Bn |
| Sep 30, 2023 | 2.74 Bn |
| Jun 30, 2023 | 2.50 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.15 Bn |
| Sep 30, 2022 | 2.04 Bn |
| Jun 30, 2022 | 2.11 Bn |
| Mar 31, 2022 | 2.60 Bn |
| Dec 31, 2021 | 2.21 Bn |
| Sep 30, 2021 | 2.04 Bn |